Trial Profile
Relation Between Safety Endpoints and Everolimus Trough Blood Level in Advanced Renal Cell Carcinoma
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 02 Aug 2017
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Pharmacokinetics
- Acronyms PEVERENAL
- 28 Apr 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov
- 21 May 2012 New trial record